Justin Yu

Jersey City, NJ

About Me

I am a life sciences researcher with a passion for working with others to solve unique and difficult problems, finding ways to leverage data that challenge the norm, and developing products that directly meet the needs of stakeholders while generating insights for future research.

My current goals are to work in health technology and develop products that will help clinicians provide better care, people live better lives, lower healthcare costs, and improve outcomes in all healthcare settings.

Database Experience

Work Experience

Self-employed: Biopharma Consultant (2021-present)

Novartis Pharmaceuticals Corp: Associate Director, US HEOR, Ophthalmology (2018-2021)

Allergan plc (now AbbVie): Manager/Senior Manager, Global HEOR, Neurosciences (2016-2018)

University of Washington/Bayer HEOR Fellowship: Postdoctoral Fellow (2014-2016)

Education

University of Washington: M.S., HEOR (2015)

University of Southern California: Pharm.D. (2014) | B.A., Biological Sciences (2010)

Manuscripts

Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 2021. doi:10.1001/jamaophthalmol.2021.4585.

Pavlovic JM, Yu JS, Silberstein SD, et al. Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia. 2019 Apr;39(4):465-476.

Law A, Yu JS, Lin W, Lynen R, Lin J. Evaluation of hospitalization costs and associated factors among maternity stays involving low-risk and moderate- to high-risk childbirths in the United States. Hosp Pract. 2017 Dec;45(5):230-237.

Law A, Yu JS, Wang W, Lynen R. Trends and regional variations in provision of contraception methods in a commercially-insured population in the US based on nationally proposed measures. Contraception. 2017 Sept;96(3):175-182.

Yu JS, Chin L, Oh J, Farias J. Performance-based risk-sharing arrangements for pharmaceutical products in the United States: a systematic review. J Manag Care Spec Phar. 2017 Oct;23(10):1028-1040.

Heresi GA, Platt DM, Wang W, Divers CH, Joish VN, Teal SA, Yu JS. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulm Med. 2017 Apr 11;17(58):1-10.

Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States. J Med Econ. 2017 Jan;20(1):54-62.

Yu JS, Hansen RN, Valderrama A, Carlson JJ. Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma. Leuk Lymphoma. 2016 Nov;57(11):2636-2643.

Resources